Ceftriaxone

Maxillary sinusitis contain either S. pneumoniae or non-typable strains of Hemophilus influenzae both beta-lactamase + and - ; .6 Moraxella catarrhalis is an occasional isolate ?pathogen ; in adults, but in children it rivals H. influenzae. Viruses are also prevalent. They mimic bacterial infections and ofttimes like allergy attacks ; predispose to secondary bacterial infections of the usual pathogens. Staph. aureus is frequently found in nasal cultures even 30 percent of normal people ; but rarely in antral puncture cultures, which suggests it is probably a contaminant. However, in the hospitalized or immunosuppressed patient, the pathogenicity of Staph. aureus is more likely. Anaerobic organisms in acute rhinosinusitis suggest dental disease as the source. Drug choices: see Guidelines for Acute Bacterial Primary for mild, no prior treatment, Rhinosinusitis, Otolaryng., Head, Neck Surg. low-resistance risk cases: 2004; 130: Suppl S34 ff.6, 7 ; The likelihood of spontaAmoxicillin high-dose ; with or without neous resolution without antibiotic therapy ; of acute clavulanate Augmentin ES XR ; rhinosinusitis is similar to that of acute otitis media half Doxycycline adults ; or more of uncomplicated mild cases ; , which suggests Cefpodoxime Vantin ; , that antibiotics should be reserved for patients with or cefdinir Omnicef ; moderate to severe symptoms and those that are progressively worsening for more than the 5-7 days of a "common-cold" ; . Inexpensive amoxicillin high-dose ; is widely recommended as the first choice antibiotic for previously untreated, mildly symptomatic, uncomplicated adult cases. For penicillin-allergic patients, the combination of erythromycin and a sulfonamide is inexpensive but troubled with side effects and bacterial resistances; doxycycline is an inexpensive option for adults. Resistances to amoxicillin and other commonly used antibiotics are prevalent, as is illustrated in the accompanying table. For a ; treatment failures, or for b ; patients in whom a treatment failure is unacceptable, or for c ; moderately to severely ill patients especially frontal or sphenoid sinusitis ; , or for d ; patients who have recently taken a penicillin or cephalosporin drug, or e ; in circumstances where resistance is prevalent, the alternative options below ; are recommended. Susceptibility of Isolates at PK PD Breakpoints 6 Percentage of Strains Susceptible Agent S. pneumoniae H. influenzae M. catarrhalis Amox clav 92 98 100 Amoxicillin 92 70 7 Cefixime 66 100 Cefpodoxime 75 100 85 Cefdinir 76 100 85 Ceftriaxone 96 100 94 Cefuroxime 73 83 50 Erythro-clarithromycin 72 0 100 Telithromycin 84 ? 100 Azithromycin 71 2 100 Clindamycin 90 0 0 Doxycycline 80 25 96 Resp. quinolones 99 100 TMP SMX 64 78 19.
Pathogen. Mycoplasma pneumoniae, C. pneumoniae and L. pneumophila are recognized as increasingly important causes of CAP. In a population-based study of all adults hospitalized for CAP within a predefined catchment area in 1991, M. pneumoniae, C. pneumoniae and Legionella spp. together accounted for 1038% of cases.5 Based on the data available, estimates of the annual number of hospitalized cases of CAP in the USA due to atypical pathogens were: Legionella spp. 800018 000, M. pneumoniae 18 700108 000 and C. pneumoniae 589049 700.5 A similar trend has been noted by other investigators and in other countries.6 Atypical pathogens may cause as many as 50% of all cases of CAP in the community.3 Part of this observed increase may be due to greater awareness and improved detection methods for atypical pathogens. Current treatment guidelines recommend a macrolide, a fluoroquinolone with good activity against S. pneumoniae or doxycycline for outpatients.1 For hospitalized patients in general medical wards, a -lactam cefotaxime, ceftriaxone or a -lactam -lactamase inhibitor ; plus a macrolide is recommended. Equally acceptable is monotherapy with a fluoroquinolone with good antipneumococcal activity and established efficacy for atypical pneumonia. For patients in intensive care units, a -lactam cefotaxime, ceftriaxone or a -lactam -lactamase inhibitor ; plus either a macrolide or a fluoroquinolone is recommended.1 The profile of 26.
A 4- to 6-week course of penicillin or ampicillin plus an aminoglycoside is currently recommended for treating enterococcal endocarditis. However, this regimen is ineffective against Enterococcus faecalis organisms with high-level aminoglycoside resistance HLAR ; . Gavalda and colleagues ` evaluated the efficacy and safety of ampicillin plus ceftriaxone for treating E. faecalis endocarditis in patients who could not tolerate aminoglycosides because of nephrotoxicity. Twentyone patients had HLAR organisms and 22 patients did not. A 6-week course effectively treated both groups. REFERENCES 1. Ahmed, A., H. Jafri, I. Lutsar, C. C. McCoig, M. Trujillo, L. Wubbel, S. Shelton, and G. H. McCracken, Jr. 1999. Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 43: 876881. 2. Dacey, R. G., and M. A. Sande. 1974. Effect of probenecid on cerebrospinal fluid concentration of penicillin and cephalosporin derivatives. Antimicrob. Agents Chemother. 6: 437441. 3. Feldman, W. E. 1976. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J. Pediatr. 88: 549552. 4. Friedland, I. R., M. Paris, S. Ehrett, S. Hickey, K. Olsen, and G. H. McCracken, Jr. 1993. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 37: 16301636. 5. Fung-Tomc, J. C., B. Minassian, B. Kolek, E. Huczko, L. Aleksunes, T. Stickle, T. Washo, E. Gradelski, L. Valera, and D. P. Bonner. 2000. Antibacterial spectrum of a novel des-fluoro 6 ; quinolone, BMS-284756. Antimicrob. Agents Chemother. 44: 33513356. 6. Henriques Normark, B., R. Novak, A. Ortqvist, G. Kallenius, E. Tuomanen, and S. Normark. 2001. Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin. Clin. Infect. Dis. 32: 552558. 7. Lutsar, I., A. Ahmed, I. R. Friedland, M. Trujillo, L. Wubbel, K. Olsen, and G. H. McCracken, Jr. 1997. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 41: 24142417.

Ing treatment, antibiotics may inhibit the establishment of colonization, whereas the same agent may promote colonization if pathogens are administered after completion of treatment during the period of recovery of the indigenous microflora ; 4 ; . Because the initial experimental results indicated that ertapenem was not detected in stool samples after 3 days of treatment despite the fact that it caused significant changes in the microflora, we measured the concentrations of ertapenem and imipenem-cilastatin in stool samples from additional mice eight per group ; after 5 days of treatment with these antibiotics. The antibiotics were administered daily in the dosages noted above. Data analyses were performed with the use of Stata software version 6.0, Stata, College Station, TX ; . A one-way analysis of variance was performed to compare the groups with P values adjusted for multiple comparisons using the Scheffe correction. The effect of antibiotic treatment on the stool microflora is shown in Fig. 1. Imipenem-cilastatin treatment did not result in significant changes in any of the measured components of the microflora in comparison to saline controls P 0.5 ; . Ertapenem, piperacillin-tazobactam, and ceftriaxone treatment resulted in significant reductions in the densities of total anaerobes, Bacteroides spp., and facultative gram-negative bacilli in comparison to saline controls P 0.03 ; . Ertapenem inhibited total anaerobes and Bacteroides spp. to a lesser degree than piperacillin-tazobactam did P 0.03 ; , but there was no significant difference in suppression of these groups between the ertapenem and ceftriaxone groups P 0.22 ; . Piperacillintazobactam treatment resulted in suppression of enterococci P 0.001 ; , whereas ertapenem and ceftriaxone promoted overgrowth of enterococci P 0.02 ; . The mean concentrations of piperacillin-tazobactam and ceftriaxone in stool sam!

500 flowering stem 1.93.1 mm diam. at base, 1.42.8 4.3 ; mm diam. when dry, stems tinted crimson or tinted purple-black, lateral flowering stems erect or decumbent, flowering stem leaves 25 pairs per stem, lowest pedicels from near base of flowering stem to near apex of flowering stem. Rosette of leaves distinct from flowering stem leaves to indistinct, leaves elliptic or ovate, 1338 55 ; mm long, 4.112 17 ; mm wide, tinted crimson or purpleblack below, apex acute to rounded, leaf flat with a V-shaped petiole, V-shaped or channelled; petiole indistinct to distinct, 6.415.3 mm long, 1.23.0 mm wide at narrowest point. Pedicels 1 per leaf axil, rarely two, 835 mm long, 0.81.4 mm diam., 0.50.8 mm diam. when dry. Flowers 435 55 ; per plant, 11.520 mm long. Calyx 6.611.9 mm long, green tinted purple-black at the lobe apices; lobes 4.69.2 mm long, 1.93.0 mm wide at base, plane, apices acute, margins smooth, sinus hairs sparse or absent. Corolla 11.019.3 mm long, white, veins purple or violet; tube 2.34.6 mm long; lobes 8.515.3 mm long, 5.48.5 mm wide, hairs below sinus present; nectary 0.41.2 mm from corolla base. Filaments 7.49.8 mm long from corolla base, 0.71.0 mm wide. Anthers 1.82.9 mm long. Stigma blue, blue-grey, or violet. Ovules 4488 per ovary. Capsule 1722 25 ; mm long. FL JanFeb. DISTRIBUTION Fig. 57 ; : Gisborne: Raukumara Range Hikurangi, Arowhenua, Honokawa, Maungawaru Plateau ; , Huiarau Range, Maungapohatu. Hawke's Bay: Kaweka Mountains. Wellington: Erua, Kaimanawa Mountains, Ruahine Range, Tararua Range. HABITAT: Alpine and subalpine, mostly on peat soils in valley head basins, Schoenus pauciflorus, Carpha alpina, Oreobolus pectinatus, Phyllachne colensoi, and Sphagnum falcatulum mossfield and cushionfield, with Drepanocladus aduncus, Coprosma perpusilla, Gentianella bellidifolia, and Euphrasia cuneata; also in subalpine shrublands of Olearia colensoi, Griselinia littoralis, Phormium cookianum, Brachyglottis eleagnifolius, and Ozothamnus leptophyllus; 10501470 m. CHROMOSOME NUMBER: n 18 Post 1983, based on two counts ; . RECOGNITION: This subspecies belongs to G. montana by virtue of its terminal flowering stems, the presence of stolons on some plants, the crimson tinting of the stem and abaxial leaf surface, and the convex curve of the calyx lobe margins. From the other taxa of G. montana it can be distinguished by the blue to violet stigmas, by the purple corolla veins, the smaller. Of Neisseria gonorrhoeae. J. Bacteriol. 136: 391-401. Harder, K. J., H. Nikaido, and M. Matsuhashi. 1981. Mutants of Escherichia coli that are resistant to certain beta-lactam compounds lack the ompF porin. Antimicrob. Agents Chemother. 20: 549-552. Hewinson, R. G., S. J. Cartwright, M. P. E. Slack, R. D. Whipp, M. J. Woodward, and W. W. Nichols. 1989. Permeability to cefsulodin of the outer membrane of Pseudomonas aeruginosa, and discrimination between f3-lactamase-mediating trapping and hydrolysis as mechanisms of resistance. Eur. J. Biochem. 179: 667-675. Hirai, K., H. Aoyama, T. Irikura, S. lyobe, and S. Mitsuhashi. 1986. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob. Agents Chemother. 29: 535-538. Hirai, K., H. Aoyama, S. Suzue, T. Irikura, S. lyobe, and S. Mitsuhashi. 1986. Isolation and characterization of norfloxacinresistant mutants of Escherichia coli K-12. Antimicrob. Agents Chemother. 30: 248-253. Hirai, K., S. Suzue, T. Irikura, S. lyobe, and S. Mitsuhashi. 1987. Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 31: 582586. Hooper, D. C., J. S. Wolfson, E. Y. Ng, and M. N. Swartz. 1987. Mechanism of action of and resistance to ciprofloxacin. Am. J. Med. 82 Suppl. 4A ; : 12-20. Hooper, D. C., J. S. Wolfson, K. S. Souza, C. Tung, G. L. McHugh, and M. N. Swartz. 1986. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob. Agents Chemother. 29: 639-644. Iyer, R., V. Darby, and I. B. Holland. 1978. Alterations in the outer membrane proteins of Escherichia coli B r associated with the presence of the R plasmid rRM98. FEBS Lett. 85: 127-132. Jaffe, A., Y. A. Chabbert, and E. Derlot. 1983. Selection and characterization of 13-lactam-resistant Escherichia coli K-12 mutants. Antimicrob. Agents Chemother. 23: 622-625. Komatsu, Y., K. Murakami, and T. Nishikawa. 1981. Penetration of moxalactam into its target proteins in Escherichia coli K-12: comparison of a highly moxalactam-resistant mutant with its parent strain. Antimicrob. Agents Chemother. 20: 613-619. Leive, L. 1974. The barrier function of the Gram-negative envelope. Ann. N.Y. Acad. Sci. 235: 109-127. Livermore, D., and T. L. Pitt. 1986. Dissociation of surface properties and "intrinsic" resistance to beta-lactams in Pseudomonas aeruginosa. J. Med. Microbiol. 22: 217-224. Lynch, M. J., G. L. Drusano, and H. L. T. Mobley. 1987. Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 31: 1892-18%. Marchou, B., F. Beilido, R. Charnas, C. Lucain, and J.-C. Pechere. 1987. Contribution of , B-lactamase hydrolysis and outer membrane permeability to ceftriaxone resistance in Enterobacter cloacae. Antimicrob. Agents Chemother. 31: 1589-1595. Medeiros, A. A., T. F. O'Brien, E. Y. Rosenberg, and H. Nikaido. 1987. Loss of OmpC porin in a strain of Salmonella typhimurium causes increased resistance to cephalosporins during therapy. J. Infect. Dis. 156: 751-757. Mitsuyama, J., R. Hiruma, A. Yamaguchi, and T. Sawai. 1987. Identification of porins in outer membrane of Proteus, Morganella, and Providencia spp. and their role in outer membrane permeation of P-lactams. Antimicrob. Agents Chemother. 31: 379-384. Nikaido, H. 1976. Outer membrane of Salmonella typhimurium. Transmembrane diffusion of some hydrophobic compounds. Biochem. Biophys. Acta 433: 118-132. Nikaido, H. 1985. Role of permeability barriers in resistance to P-lactam antibiotics. Pharmacol. Ther. 27: 197-231. Nikaido, H. 1989. Role of the outer membrane of Gram-negative bacteria in antimicrobial resistance, p. 1-34. In L. E. Bryan ed. ; , Handbook of experimental pharmacology, vol. 91. Microbial Resistance to Drugs. Springer-Verlag KG, Berlin. Nikaido, H., and R. E. W. Hancock. 1986. Outer membrane permeability of Pseudomonas aeruginosa, p. 145-193. In J. R and cerezyme. Top action of ceftriaxone-bc: microbiology: ceftriaxone is a semisynthetic broad spectrum cephalosporin antibiotic with bactericidal activity against gram negative and gram positive bacteria including those with beta-lactamases ; ceftriaxone is usually active against the following pathogens: gram negative anaerobes: e. There are no firm guidelines as to the duration of parenteral therapy for osteomyelitis, but generally a minimum of 6 to weeks is sufficient in pyogenic infections.97 Although it is not proven to be of benefit, some practitioners prefer to give an additional 1 to 2 months of oral antibiotic therapy. Recommendations for specific antibiotic drugs are outlined in Table 2. In the case of Pott disease, treatment lasts for a mean of 12 months, with variations in duration and type of chemotherapy depending on regional resistance patterns. Initially, isoniazid, ethambutol, rifampin, and pyrazinamide are prescribed for the first 2 months. If no information on sensitivities is available, isoniazid, ethambutol, and rifampin are continued for 12 months. If sensitivities are known, two drugs can be used. If isoniazid and rifampin are active, they are continued for 12 months. If other combinations are used, therapy is extended to 18 to months. In immunocompromised patients, indinavir and rifabutin are added. Fungal granulomatous infections are commonly treated with amphotericin B or itraconazole. Antibiotic use in discitis in children ; is controversial because the course of the disease appears to be benign.26, 104, 112, 126 Some authors argue that the use of antibiotic drugs will abbreviate the course of the illness122 and even decrease the likelihood of recurrence. Nevertheless, in one series only three of 20 patients who received no antibiotics had recurrences.26 We recommend the use of antibiotic medications in the setting of discitis if positive cultures are obtained, recurrences of back pain are accompanied by systemic signs elevated ESR, CRP level, WBC count, or temperature ; , or if the patient exhibits clinical progression of disease despite adequate immobilization. Ceftriaxone is recommended in children 3 years of age or younger because of the possibility of infection by Haemophilus influenzae. Three quarters of patients will respond to nonsurgical treatment measures, 33, 97, 109, although it is worth noting that in one series, medical treatment failed in 13 of patients who had a compromised immune status and an unchanged ESR.19 Medical management is considered to be a failure when symptoms are persistent or worsening, CRP level or ESR remains elevated, or neuroimaging demonstrates continuing bone destruction after 1 month of specific treatment in pyogenic infections or 3 months in Pott disease. Medical management of spinal canal infection is mentioned separately here because of the controversies that exist. There have been reported cases in which spinal epidural abscess and intramedullary abscesses have been treated medically; 47, 67, 74, however, there are no clear indications concerning when a medical approach is more appropriate than surgery. Leys, et al., 67 define four patient groups that are candidates for nonsurgical management: high-risk surgical candidates, neurologically intact and stable patients, those with complete paresis for more than 72 hours, or with extensive diffuse abscess formation. If medical management is chosen, the patient must be monitored closely. Frequent MR imaging as well as antibiotic therapy tailored specifically to the infectious agent is mandatory. Intravenous antibiotic administration should be of longer duration than in cases in which surgical drainage is accomplished. If no infectious agent can be recovered on either blood culture or CT-guided biopsy sampling, an unequivocal indication for surgical management exists. Ra7 and cerivastatin. Table I. Comparison of the MICs and of peak and trough serum concentrations of antibiotics Group Trovafloxacin Vancomycin Ceftriaxone Penicillin Quinupristindalfopristin.

Buy Ceftriaxone online Meningitis ; . For the treatment of infants whose mothers have gonococcal infections, recommended treatment is ceftriaxone 25-50 mg kg IV or IM for 1 dose maximum 125 mg ; . For the treatment of children 45 kg, recommended therapies are similar to those for adults. For the treatment of children 45 kg with uncomplicated gonococcal vulvovaginitis, cervicitis, urethritis, pharyngitis, or proctitis, recommended therapy includes ceftriaxone 125 mg IM for 1 dose; alternative therapy is spectinomycin * 40 mg kg IM for 1 dose maximum 2 g ; , though unreliable in the treatment of pharyngitis. For the treatment of children 45 kg who have bacteremia or arthritis, recommended therapy includes ceftriaxone 50 mg kg maximum dose 1 g ; IM for 1 dose for 7 days. For the treatment of children 45 kg who have bacteremia or arthritis, recommended therapy includes ceftriaxone 50 mg kg IM or IV for 1 dose for 7 days. For the prophylaxis of neonates for ophthalmia neonatorum, recommended prophylactic therapy includes erythromycin 0.5% ; or tetracycline 1% ; ophthalmic ointment for 1 application and cetuximab. Buy Ceftriaxone online The majority of patients with heart failure seen in clinical practice belong to this group. Cardiac pump failure is associated with myocardial failure and depression of myocardial contractility. Myocardial failure develops either because of a direct loss of the contractile units myocytes ; or because of excessive mechanical loading. In the presence of severe mechanical problems, e.g. valvular aortic stenosis or regurgitation, or mitral insufficiency it is important to identify the extent of depression of myocardial contractility. Your Money page 2 Tips and advice on handling your money Food & Nutrition page 4 & 12 Recipes and healthy living Home and Garden page 6 Tips, news and advice Pets page 7 Pet tip of the week Featured Properties page 8 Granite Bay Focus page 9 Your Health page 11 Health issues and related articles Travel page 14 Prepare for the Ultimate Vacation! Kids Corner page 14 Games, jokes and fascinating facts! Out Of Town Properties page 15 Community Activity Report page 16 and chamomile! Discount Ceftriaxone In addition once you have managed the airway you need to ventilate the patient either with mouth-to-mouth mask or using a mask - self inflating bag combination e.g. Ambubag ; . The reason for discussing this is that you need to decide how much airway equipment to stock. Our view is that there is relatively little need to stock anything more than simple airway devices such as oral or nasal airways unless you are planning and have the skills ; to give an anaesthetic for the simple reason that anyone one who requires advanced airway management is likely to be unsalvageable in an austere situation. If simple devices are not sufficient then they are likely to die regardless and introducing relatively complicated airway devices will not help. This, however, is an individual decision and ceftriaxone. Offering activities that allow students to experience mandarins using their senses may help increase interest, awareness and support for eating more fruits and vegetables. Tools: n One Satsuma, tangerine and tangelo variety * per group; harvest from school garden n Paper and pencils n One cutting board and knife per group Citrus fruits are sources of flavonoids and chaparral. The Table reports the mean S.D. ; adhesion values for S. aureus strains challenged with the three cephalosporins. The 1 2 MIC concentration produced the greatest inhibition of bacterial adhesion, as one would expect, and the gradual return towards the control values was similar for cefodizime and cefotaxime, with a significant reduction from 1 2 to MIC, while ceftriaxone reduction was significant only up to 1 MIC. From these concentrations down to 1 128 MIC, the adhesion oscillated around values comparable to those for the controls. Figure 1 shows examples of the shapes of S. aureus cells growing under normal conditions and after incubation with 1 2 MIC cefodizime. Many of the bacterial cells were enlarged 80. Side effects of Ceftriaxone Derived from thyme, lemon, and tea tree-oils, our Elite Para-Pharmaceutical Hand Treatment Cream repairs overworked hands, while penetrating deeply into exposed cracks in the skin. Formulated to repair visibly dry and cracked areas, this nourishing cream protects while it revitalizes. The result is a healthier, more youthful appearance of the hands. This hand cream is for severely dry and cracked skin. To Use: Apply as often as desired spreading generously over hands and cuticles. Ingredients: Thyme oil, lemon oil, tea tree oil, neroli oil, deionized water, cyxlomethicone, dimethiconol, emulsifying wax, cyclomethicone and charcoal. In the European market, bringing in over 0 million to Germany and France. The leaf products are used for peripheral vascular circulatory problems, which create a number of disease conditions especially in elderly populations, and as an antagonist to a platelet activating factor. A German company has its tree-growing and leaf-production operation on a 1, 900-acre farm. Cotton-picking machines are used to beat off the leaves, which go into the drying shed and celestone. FIG. 1. Transmission electron micrograph of negatively stained T. pallidum Nichols strain ; from a rabbit 4 h after treatment with 5 , umol of ceftriaxone per kg. Note the granular appearance of the cell body, indicating penetration of PTA. Bar, 0.5 p.m and chlorambucil. CSL's Fluvax influenza vaccine has been the market leader in Australia for many years. Future growth in vaccine sales will come from broadening vaccine uptake in Australia and developing new international business. History of Ceftriaxone Cetriaxone, cedtriaxone, cefgriaxone, cefftriaxone, cefttriaxone, ceftriaxome, ceftriacone, cevtriaxone, ecftriaxone, veftriaxone, csftriaxone, ceffriaxone, ceftriaoxne, cef5riaxone, ceftrriaxone, c4ftriaxone, ceftriaxonw, ceftrixone, ceftriaxnoe, ceftriax0ne, ceftroaxone, ceftriaxon, eftriaxone, ceftrixaone, cefyriaxone, cftriaxone, ceftriadone, ceftriax9ne, ceftriaxon4, ceeftriaxone, ceftriaxond, ceftriaxoe, ceftraxone, ceft4iaxone, ceftriiaxone, cefriaxone, ceftriaxkne, cegtriaxone, cefhriaxone, ceftiaxone, deftriaxone, cetfriaxone, ceftr8axone, cfetriaxone, ceftriazone, xeftriaxone, cceftriaxone, feftriaxone.